Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Travere Therapeutics Inc shares valued at $8,263 were sold by Cline Christopher R. on Sep 03 ’25. At $18.20 per share, Cline Christopher R. sold 454 shares. The insider’s holdings dropped to 92,202 shares worth approximately $2.52 million following the completion of this transaction.
Also, Cline Christopher R. sold 119 shares, netting a total of over 2,345 in proceeds. Following the sale of shares at $19.71 each, the insider now holds 92,083 shares.
Before that, Cline Christopher R. had sold 470 shares from its account. In a trade valued at $8,136, the CHIEF FINANCIAL OFFICER traded Travere Therapeutics Inc shares for $17.31 each. Upon closing the transaction, the insider’s holdings decreased to 470 shares, worth approximately $2.53 million.
Analysts at Citigroup resumed the stock at ‘”a Buy”‘ outlook in a report released in mid June. As of January 10, 2025, Cantor Fitzgerald has initiated its “an Overweight” rating for TVTX. Earlier on October 21, 2024, Wells Fargo upgraded its rating. Their new recommendation was “an Overweight” for TVTX stock which previously was a “an Equal weight”.
Analyzing TVTX Stock Performance
On last trading session, Travere Therapeutics Inc [NASDAQ: TVTX] rose 26.20% to $27.31. The stock’s lowest price that day was $24.9101, but it reached a high of $28.6927 in the same session. During the last five days, there has been a surge of approximately 39.27%. Over the course of the year, Travere Therapeutics Inc shares have jumped approximately 148.72%. Shares of the company reached a 52-week high of $28.69 on 09/10/25 and a 52-week low of $12.91 on 04/09/25.
Support And Resistance Levels for Travere Therapeutics Inc (TVTX)
According to the 24-hour chart, there is a support level at 25.25, which, if violated, would cause prices to drop to 23.19. In the upper region, resistance lies at 29.03. The next price resistance is at 30.75. RSI (Relative Strength Index) is 86.74 on the 14-day chart, showing overbought technical sentiment.
Is Travere Therapeutics Inc subject to short interest?
Stocks of Travere Therapeutics Inc saw a sharp steep in short interest on 2025-08-15 dropping by -0.75 million shares to 12.11 million. Data from Yahoo Finance shows that the short interest on 2025-07-15 was 12.86 million shares. A decline of -6.21% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 8.47 of the overall float, the days-to-cover ratio (short ratio) decline to 8.47.
Which companies own the most shares of Travere Therapeutics Inc (TVTX)?
In terms of Travere Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 21.5 in the next 12 months, down nearly -0.65% from the previous closing price of $21.64. Analysts anticipate Travere Therapeutics Inc stock to reach 33 by 2025, with the lowest price target being 12. In spite of this, 8 analysts ranked Travere Therapeutics Inc stock as Buy at the end of 2025.
